Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naive adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES)

Autor: R. W. ten Kate, Selwyn H. Lowe, Elly A. M. Hassink, Job R. Juttmann, Peter P. Koopmans, I. van der Tweel, Lange Jm, Jan C. C. Borleffs, G. Schreij, Annemarie M. J. Wensing, Clemens Richter
Přispěvatelé: Infectious diseases
Rok vydání: 2005
Předmět:
Male
HIV Infections
Pharmacology
Gastroenterology
Antiretroviral Therapy
Highly Active
Effective Primary Care and Public Health [EBP 3]
Perception and Action [DCN 1]
Pharmacology (medical)
Didanosine
Nelfinavir
HIV-INFECTED ADULTS
SAQUINAVIR
Stavudine
Lamivudine
Viral Load
DOUBLE-BLIND TRIAL
Infectious Diseases
RNA
Viral
Reverse Transcriptase Inhibitors
Female
medicine.drug
Adult
medicine.medical_specialty
Nevirapine
Anti-HIV Agents
INCLUDING NEVIRAPINE
LAMIVUDINE
HIV-1-INFECTED PATIENTS
CLINICAL-TRIAL
Invasive mycoses and compromised host [N4i 2]
human immunodeficiency virus type 1
Internal medicine
medicine
Humans
once-daily dosed highly active antiretroviral therapy
Ritonavir
antiretroviral therapy-naive
business.industry
Poverty-related infectious diseases [N4i 3]
HIV Protease Inhibitors
RANDOMIZED-TRIAL
CD4 Lymphocyte Count
COMBINATION THERAPY
Regimen
TRIPLE
HIV-1
Microbial pathogenesis and host defense [UMCN 4.1]
business
Saquinavir
Zdroj: Clinical trials, 6(5), 235-245. SAGE Publications Inc.
Hiv Clinical Trials, 6, 235-45
Hiv Clinical Trials, 6, 5, pp. 235-45
HIV clinical trials, 6(5), 235-245. Taylor and Francis Ltd.
ISSN: 1528-4336
Popis: Contains fulltext : 47519.pdf (Publisher’s version ) (Closed access) BACKGROUND: To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD: HIV-1-infected, antiretroviral drug-naive adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or simplified once-daily dosed antiretroviral regimens consisting of nevirapine, didanosine, and lamivudine (regimen B) or saquinavir, ritonavir, didanosine, and lamivudine (regimen C). RESULTS: At 48 weeks of therapy, the proportion of patients with a blood plasma HIV-1 RNA concentration (pVL)
Databáze: OpenAIRE
Externí odkaz: